Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES PLIMPTON

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1891777835
CMS profile
267685
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$4,550.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $4,550.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $4,550.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES PLIMPTON

NPI 1891777835 · CMS profile ID 267685

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891777835?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891777835?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891777835?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1891777835?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $4,550.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $4,550.0001/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743189229 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,037.66 8
PY2020 $4,550.00 1
PY2024 $164.80 3
PY2025 $63.56 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $280,140.77 30
PY2024 Principal investigator $631,342.46 58
PY2023 Principal investigator $604,319.86 129
PY2022 Principal investigator $1,688,412.68 133
PY2021 Principal investigator $3,601,852.60 159
PY2020 Principal investigator $853,852.30 65
PY2019 Principal investigator $195,210.58 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $79,209.86 12/31/2024 Non-covered Recipient Entity
Velocity Clinical Research, Phoenix
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136437935
Principal investigator 1 ModernaTX, Inc. $95,409.90 12/20/2024 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147171218
Principal investigator 1 Organon LLC $61,168.80 12/11/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1125523593
Principal investigator 1 ModernaTX, Inc. $80,744.30 11/21/2024 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147171178
Principal investigator 1 ModernaTX, Inc. $7,000.00 11/20/2024 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 4, Randomized, Observer-blind, Placebo-controlled, Crossover Study to Assess Cardiac Troponin Levels after mRNA-1273.712 Vaccine in Participants 12 through 30 years of Age No dispute reported 06/30/2026 1147171186
Principal investigator 1 Novo Nordisk AS $2.60 11/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9388-7741 No dispute reported 06/30/2026 1097190267
Principal investigator 1 Novo Nordisk AS $9.80 11/13/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
NN9388-7741 No dispute reported 06/30/2026 1097197926
Principal investigator 1 ModernaTX, Inc. $166.72 10/16/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135423
Principal investigator 1 Merck Sharp & Dohme LLC $296.94 09/30/2024 Non-covered Recipient Entity
Velocity Clinical Research, Phoenix
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136437939
Principal investigator 1 PFIZER INC. $26,227.10 09/28/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1130897770
Principal investigator 1 PFIZER INC. $26,227.10 09/28/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1130899923
Principal investigator 1 ModernaTX, Inc. $890.00 09/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135113
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/25/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147135115
Principal investigator 1 SANOFI US SERVICES INC. $590.00 09/20/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States No dispute reported 06/30/2026 1128715905
Principal investigator 1 SANOFI US SERVICES INC. $550.00 09/20/2024 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States No dispute reported 06/30/2026 1128728544
Principal investigator 1 PFIZER INC. $14,433.15 09/13/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1130897766
Principal investigator 1 PFIZER INC. $14,433.15 09/13/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1130899926
Principal investigator 1 ModernaTX, Inc. $2.94 09/06/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134911
Principal investigator 1 ModernaTX, Inc. $16.25 09/06/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134913
Principal investigator 1 ModernaTX, Inc. $208.00 09/06/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134915
Principal investigator 1 ModernaTX, Inc. $5,733.00 09/06/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134917
Principal investigator 1 ModernaTX, Inc. $1,306.25 09/06/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134919
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,362.75 08/23/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1110834909
Principal investigator 1 ModernaTX, Inc. $1,390.61 08/21/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147134751
Principal investigator 1 ModernaTX, Inc. $1,750.00 08/16/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147134785
Principal investigator 1 PFIZER INC. $17,199.25 07/30/2024 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1131045334
Principal investigator 1 Merck Sharp & Dohme LLC $28,693.00 07/03/2024 Non-covered Recipient Entity
Velocity Clinical Research, Phoenix
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1136437930
Principal investigator 1 ModernaTX, Inc. $1,520.28 06/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133947
Principal investigator 1 ModernaTX, Inc. $100.00 06/05/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147134317
Principal investigator 1 ModernaTX, Inc. $3,705.78 05/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133619
Principal investigator 1 ModernaTX, Inc. $104.00 05/01/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147133633
Principal investigator 1 ModernaTX, Inc. $1,057.16 04/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133277
Principal investigator 1 ModernaTX, Inc. $416.00 04/26/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147133363
Principal investigator 1 PFIZER INC. $40,000.00 04/18/2024 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1131091741
Principal investigator 1 ModernaTX, Inc. $297.83 04/12/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147133383
Principal investigator 1 ModernaTX, Inc. $1,254.07 04/12/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147133389
Principal investigator 1 ModernaTX, Inc. $377.65 04/10/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133329
Principal investigator 1 ModernaTX, Inc. $48,590.22 04/05/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147133395
Principal investigator 1 ModernaTX, Inc. $4,851.08 04/03/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147133349
Principal investigator 1 ModernaTX, Inc. $1,748.50 03/27/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147132765
Principal investigator 1 ModernaTX, Inc. $300.00 03/20/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132695
Principal investigator 1 ModernaTX, Inc. $1,100.38 03/20/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132713
Principal investigator 1 ModernaTX, Inc. $1,223.88 03/08/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132747
Principal investigator 1 Exeltis, USA Inc. $12,000.00 03/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - PHOENIX
LR-303 No dispute reported 06/30/2026 1149986619
Principal investigator 1 Exeltis, USA Inc. $2,000.00 03/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - PHOENIX
LR-303 No dispute reported 06/30/2026 1149986623
Principal investigator 1 Exeltis, USA Inc. $1,200.00 03/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - PHOENIX
LR-303 No dispute reported 06/30/2026 1149986628
Principal investigator 1 Exeltis, USA Inc. $1,500.00 03/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - PHOENIX
LR-303 No dispute reported 06/30/2026 1149986631
Principal investigator 1 Exeltis, USA Inc. $2,000.00 03/07/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH - PHOENIX
LR-303 No dispute reported 06/30/2026 1149986635
Principal investigator 1 ModernaTX, Inc. $2,236.00 02/16/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132089
Principal investigator 1 ModernaTX, Inc. $150.00 02/14/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132003
Principal investigator 1 ModernaTX, Inc. $500.00 02/14/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132005
Principal investigator 1 ModernaTX, Inc. $1,780.00 02/14/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147132007
Principal investigator 1 ModernaTX, Inc. $1,400.00 02/02/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147132257
Principal investigator 1 SANOFI PASTEUR INC. $3,708.00 02/02/2024 Non-covered Recipient Entity
Medpharmics,LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 1128700178
Principal investigator 1 GlaxoSmithKline, LLC. $12,500.00 01/26/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE I/II, OBSERVER-BLIND, RANDOMISED, PLACEBO-CONTROLLED, MULTI-CO No dispute reported 06/30/2026 1127536810
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 01/16/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127536808
Principal investigator 1 ModernaTX, Inc. $169.00 01/10/2024 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1147131791
Principal investigator 1 GlaxoSmithKline, LLC. $281.16 01/02/2024 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127536806